Source: The BSC Group, LLC Chicago, IL, April 24, 2012 –(PR.com)– The BSC Group, LLC, a leading commercial real estate financing advisor and provider of debt and equity capital solutions for commercial property owners, announced recent financing transactions totaling…
May 17, 2012
NEW YORK, NY, Apr 24, 2012 (MARKETWIRE via COMTEX) –
Infocast is delighted to announce its upcoming Power Generation
Asset Financing Summit to be held at the Digital Sandbox in New York,
NY from May 21-23, 2012. The Summit, featuring two exceptional
events, will be kicked off by an Executive Briefing that offers an
excellent opportunity to gain high-level insight into the major
trends impacting the value of power assets. Key dealmakers and
financiers will gather to explore the latest trends and
opportunities, while providing the market intelligence that you will
need to get the inside track on the market.
The changing state of the U.S. power markets coupled with a series of
upcoming refinancings are driving exciting new opportunities in power
generation asset mergers and acquisitions. Dealmaking has been robust
and more deals are projected. Yet, uncertainty over the future of
U.S. power markets and the ramifications of the Eurozone crisis
require dealmakers and financiers to keep close tabs on the pulse of
the market in order to successfully identify opportunities, make
realistic valuations and obtain the best financing.
To get the latest industry intelligence, attend Power Generation
Asset Financing Summit where key market players will provide key
assessments of ongoing challenges and changes. These players include
senior representatives from AES Corporation, Constellation Energy,
Denham Capital, Duke Energy, Energy Investors Fund, Essential Power,
LS Power, New Wave Energy Capital Partners, NRG Energy, Tenaska
Capital Management and many more! Buyers and sellers, institutional
investors, private equity, hedge funds, underwriters and other market
players will all be on hand to meet, network, and share the latest
information on the state of dealmaking and deal financing in today’s
environment.
Marathon Capital, LLC, Chadbourne & Parke LLP and Orrick sponsor this
year’s Summit.
For more information, to REGISTER for the Summit, or to join us as a
Speaker or a Sponsor, please visit the event website at
www.infocastinc.com/powerasset12 or contact Infocast at 818-888-4444.
About Infocast
For over 25 years, Infocast has produced the highest
quality events, tailored to the needs of the industries we serve. We
intensively research the marketplace, pulling from an extensive
network of experts to give you the information and connections to
succeed. For more information, please visit us at
www.infocastinc.com .
Contact:
Nick Eustrom
818-888-4444, ext. 17
SOURCE: Infocast
Copyright 2012 Marketwire, Inc., All rights reserved.
Financial Glossary
Words used in this article:
May 12, 2012
DURHAM, N.C., April 24, 2012 /PRNewswire via COMTEX/ –
Argos Therapeutics Inc. today announced that it has secured a $25 million Series D financing to support the commencement of its Phase 3 ADAPT study in patients with newly diagnosed, metastatic renal cell carcinoma (mRCC) in mid-2012. The financing was led by Forbion Capital and included other existing investors, including TVM Capital, Lumira Capital, Intersouth Partners, Caisse de depot et placement du Quebec, Morningside Group, and Aurora Funds. Argos’s Arcelis(TM) immunotherapy, AGS-003, has also been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with mRCC. The international Phase 3 ADAPT study is expected to commence in mid-2012 under a revised Special Protocol Assessment (SPA) agreement with the FDA. This pivotal study will evaluate the addition of AGS-003 to standard therapy versus standard therapy alone.
“With this latest round of financing Argos is well positioned to execute its business strategy and move forward with the planned Phase 3 ADAPT study of its lead product candidate, AGS-003,” said Jeff Abbey, president and chief executive officer of Argos. “We recently presented updated results at the 2012 ASCO Genitourinary Cancers Symposium from a Phase 2 study of AGS-003 demonstrating prolonged survival in newly diagnosed, metastatic RCC patients. Importantly, we also demonstrated that our intended mechanism of action, the induction of memory T cells, significantly correlated with improved overall survival. The Phase 3 ADAPT study is designed to confirm these positive results and demonstrate that AGS-003 may be an effective, safe and readily combinable therapeutic option for patients with metastatic RCC.”
Charles Nicolette, Ph.D., chief scientific officer and vice president of research and development of Argos, said, “The Fast Track designation by the FDA recognizes the need for more effective treatments in metastatic RCC.”
The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs for the treatment of serious or life-threatening diseases with the potential to address unmet medical needs. Fast Track designation allows for the review timeline to be truncated to six months compared to the traditional 12 months.
The Phase 3 ADAPT study is a randomized, multicenter, open-label study of AGS-003 in combination with sunitinib compared to sunitinib plus placebo. Argos plans to enroll approximately 450 mRCC patients at approximately 100 clinical sites in North America and Europe. The primary endpoint for the ADAPT study is overall survival. Additional endpoints include overall response, immune response, progression-free survival and safety.
Regarding the Phase 2 clinical study, 21 patients with newly diagnosed metastatic clear cell RCC were enrolled. Treatment consisted of six-week cycles of sunitinib, four weeks on and two weeks off, plus AGS-003, which was administered as an intradermal injection every three weeks for five doses, and then every 12 weeks until progression in combination with sunitinib. Results presented during the 2012 ASCO Genitourinary Cancers Symposium indicated that the median progression-free survival in patients with newly diagnosed, unfavorable risk mRCC was 11.2 months and estimated Kaplan-Meier median overall survival was 29.3 months in this study, based upon follow-up through January 2012. In addition, AGS-003 was well tolerated in combination with sunitinib, with no immunotherapy related serious adverse events observed.
About the Arcelis(TM) Technology
Arcelis is Argos’s proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies. This platform is based on optimizing a patient’s own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient’s disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA (“mRNA”) isolated from the patient’s disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is fully personalized for each patient’s disease.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis(TM) technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient’s dendritic cells to activate an immune response specific to the patient’s disease. Argos’ most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV.
Contact:
David Schull or Andreas MarathovouniotisRusso Partners LLC(212) 845-4271 or (212) 845-4235david.schull@russopartnersllc.com or andreas.marathis@russopartnersllc.com
Jeff AbbeyArgos Therapeutics(919) 287-6308jabbey@argostherapeutics.com
SOURCE Argos Therapeutics Inc.
Copyright (C) 2012 PR Newswire. All rights reserved
Financial Glossary
Words used in this article:
May 11, 2012
RICHMOND, Va., April 24, 2012 /PRNewswire via COMTEX/ –
BB&T Capital Markets served as senior managing underwriter on behalf of Longhorn Village for its debt refinancing, valued at more than $112 million.
The transaction consisted of adjustable and fixed-rate tax-exempt and taxable fixed-rate bonds enabling Longhorn Village to refinance its outstanding debt and provide additional working capital. Brandon Powell and Rick Lohr led the BB&T team.
Longhorn Village, based in Austin, Texas, is a non-profit continuing care retirement community that is sponsored by The Ex-Students’ Association of the University of Texas. The community provides housing and health care related services to the elderly, offering an environment for continued learning, wellness, friendship, and a sense of community.
The transaction closed on March 29.
About BB&T Capital Markets BB&T Capital Markets provides a full-spectrum of capital and advisory solutions including M&A advisory, equity and debt underwriting, sales and trading, research, corporate banking and syndicated finance. More information about BB&T Capital Markets is available at
http://www.bbtcapitalmarkets.com .
About BB&T BB&T Corporation
/quotes/zigman/180308/quotes/nls/bbt BBT
+1.73%
is one of the largest financial services holding companies in the U.S. with $174.8 billion in assets and market capitalization of $21.9 billion, as of March 31, 2012. Based in Winston-Salem, N.C., the company operates approximately 1,800 financial centers in 12 states and Washington, D.C., and offers a full range of consumer and commercial banking, securities brokerage, asset management, mortgage and insurance products and services. A Fortune 500 company, BB&T is consistently recognized for outstanding client satisfaction by J.D. Power and Associates, the U.S. Small Business Administration, Greenwich Associates and others. More information about BB&T and its full line of products and services is available at
www.BBT.com .
This news release is neither an offer to sell nor a solicitation of an offer to buy any securities.
BB&T Capital Markets is a division of Scott & Stringfellow LLC, member NYSE/FINRA/SIPC. Scott & Stringfellow is a wholly-owned nonbank subsidiary of BB&T Corporation
/quotes/zigman/180308/quotes/nls/bbt BBT
+1.73%
. Not a deposit, not FDIC insured, not guaranteed by the bank, not insured by any federal government agency and may go down in value.
SOURCE BB&T Corporation
Copyright (C) 2012 PR Newswire. All rights reserved
/quotes/zigman/180308/quotes/nls/bbt
Add to portfolio
BBT
BB&T Corp.
US
: U.S.: NYSE
$
31.77
+0.54
+1.73%
Volume: 3.51M
May 10, 2012 4:02p
P/E Ratio15.03
Dividend Yield2.52%
Market Cap$21.82 billion
Rev. per Employee$298,805
/quotes/zigman/180308/quotes/nls/bbt
Add to portfolio
BBT
BB&T Corp.
US
: U.S.: NYSE
$
31.77
+0.54
+1.73%
Volume: 3.51M
May 10, 2012 4:02p
P/E Ratio15.03
Dividend Yield2.52%
Market Cap$21.82 billion
Rev. per Employee$298,805
Financial Glossary
Words used in this article:
May 11, 2012
PORTLAND, OR, Apr 24, 2012 (MARKETWIRE via COMTEX) –
Chirpify, the Twitter Commerce Platform, today announced it has
secured $1.3 million in series A financing. Voyager Capital, angel
investor Geoff Entress, BuddyTV CEO Andy Liu, former Facebook
executive Rudy Gadre, HootSuite CEO Ryan Holmes, and TiE Oregon
Angels all contributed to this first round of financing for the
company.
“Twitter is a tremendous platform for brands, retailers, politicians,
musicians and others to engage fans, yet with more than 140 million
users there’s still no way to directly exchange goods and currency,”
said HootSuite CEO Ryan Holmes. “Chirpify provides a unique approach
to fill this void by processing transactions without ever having to
leave Twitter.”
In addition to securing funding, Chirpify is launching its new
Twitter Commerce for Digital Content platform, a way for musicians to
sell and consumers to buy digital content like songs and concert
tickets via Twitter. Chirpify’s Twitter commerce platform provides a
simple way to turn tweets into transactions, and the new digital
content offering extends that same power to any content.
“Chirpify now makes it possible to sell digital content in-stream on
Twitter, enabling musicians and artists to sell direct to their fans
and control their own distribution,” said Chirpify CEO and Founder
Chris Teso. “People already use Twitter to follow the brands,
musicians and others they care about, so why can’t they get the
latest product or hot new song right through Twitter? Now they can.”
According to Jake Schaefer with Minneapolis hip-hop label Rhymesayers
Entertainment, “Chirpify allows us to deliver digital music and goods
to our fans in a way that’s most convenient to them by providing a
truly mobile shopping experience.”
How Twitter Commerce for Digital Content Works
Selling and
purchasing digital content with Chirpify is easy. Artists simply
upload content to their Chirpify dashboard, and click to tweet.
Consumers use Chirpify to securely connect their Twitter and PayPal
accounts, and once linked reply to the tweet with something as simple
as “@favoriteartist buy (insert digital content).” Chirpify then
sends a secure download link via direct message and/or email to
download that song or other digital content.
More Than Digital Content
Chirpify has solved a huge problem: how to
monetize social media. It gives individuals, companies, organizations
– anyone — the ability to buy, sell, donate or pay someone with a
simple tweet. Because it works anywhere that Twitter does, any user
on any mobile device, tablet or computer can use Chirpify to conduct
seamless and secure transactions. While Chirpify is a complete
commerce platform, it also offers deep integration with existing
e-commerce storefronts, including Magento, for back-end fulfillment,
listing and transaction management. To use Chirpify, merchants simply
click the “list on Twitter” button when drafting an item listing for
sale in their e-commerce or Chirpify dashboard. They can also use
Chirpify to set the item price, quantity, shipping price and shipping
timing. For Chirpify plans and pricing, go to
http://chirpify.com/twitter_commerce .
About Chirpify
Chirpify (
www.chirpify.com ) is a seamless payment
system for Twitter commerce. With full integration to PayPal,
Chirpify enables businesses to buy, sell, donate and exchange funds
on Twitter, turning tweets into immediate transactions. Based in
Portland, Oregon, the Chirpify platform is the first social commerce
system to offer direct monetization through Twitter. To learn more
about Chirpify and begin sending or receiving payments today, visit
www.chirpify.com .
Contact:
Andrew Goss
VOXUS PR for Chirpify
Email Contact
253.444.5446
SOURCE: Chirpify
http://www2.marketwire.com/mw/emailprcntct?id=99834C2C34219222
Copyright 2012 Marketwire, Inc., All rights reserved.
Financial Glossary
Words used in this article:
May 10, 2012
TORONTO, ONTARIO, Apr 23, 2012 (MARKETWIRE via COMTEX) –
Crystallex International Corporation (otcqb:CRYFQ) (“Crystallex”
or the “Company”) announced today that the Ontario Superior Court of
Justice (Commercial List) issued an order (the “CCAA Order”)
approving the Company’s debtor-in-possession (DIP) financing of
US$36,000,000 provided by an entity managed by Tenor Capital
Management Company LLC (together with any successors, assigns or
transferees as permitted, the “Lender”).
In accordance with the terms of the senior secured credit agreement
pursuant to which the DIP financing is expected to be provided (the
“Credit Agreement”), an initial tranche of US$9 million would be
available on the execution of such agreement and the satisfaction of
certain conditions precedent, which funds would allow the Company (i)
to repay its previously announced US$3.125 million bridge loan
provided by Tenor Special Situations Fund, L.P., which has become due
and payable, and (ii) to fund its operations, including the
prosecution of its arbitration claim against the government of
Venezuela. The Company is diligently working towards the satisfaction
of such conditions precedent and as a result expects that the initial
advance will be made shortly and in any event by the end of April.
Three subsequent tranches of US$12 million, US$10 million and US$5
million each would also be made available upon the Company meeting
certain conditions in accordance with the terms of the Credit
Agreement and the CCAA Order, as applicable. The holders of the
US$100,000,000 unsecured notes issued by the Company have served the
Company with a motion for leave to appeal the CCAA Order. The appeal
process has been expedited.
If any appeal of the CCAA Order has been dismissed or the period for
an appeal of such order has expired, the Credit Agreement would also
provide for additional compensation to the Lender which would be
dependent on the amount of the net proceeds realized from an award or
settlement in respect of the Company’s arbitration with the
government of Venezuela and which, at the option of the Lender, could
be converted into up to 35% of the equity of the Company. In
addition, the Credit Agreement would in such circumstances require
certain changes to be made to the governance of Crystallex, including
changes to the composition of the board of directors of the Company
such that the Lender would have the right to appoint 2 of the 5
directors of the Company.
The Court has also approved a discretionary management retention plan
of the Company, pursuant to which, upon a successful conclusion of
the arbitration with the government of Venezuela, retention amounts
may be paid at the discretion of an independent committee. The
independent committee can award amounts, depending on certain
factors, ranging from zero to a variable cap that cannot exceed ten
percent of the amount of any award or settlement after the payment of
liabilities of the Company.
Additional information relating to the Credit Agreement and other
matters pertaining to the Company’s proceeding under the Companies’
Creditors Arrangement Act (Canada) is and will be available at
www.sedar.com under the Company’s profile and on the monitor’s
website at
www.ey.com/ca/crystallex .
About Crystallex
Crystallex International Corporation is a Canadian based mining
company, with a focus on acquiring, exploring, developing and
operating mining projects. Crystallex has successfully operated an
open pit mine in Uruguay and developed and operated three gold mines
in Venezuela. The Company’s principal asset is its international
claim in relation to its investment in the Las Cristinas gold project
located in Bolivar State, Venezuela.
SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS: Certain statements
included or incorporated by reference in this press release,
constitute forward-looking statements. The words “believe,” “expect,”
“anticipate,” “contemplate,” “target,” “plan,” “intends,” “continue,”
“budget,” “estimate,” “may,” “schedule” and similar expressions
identify forward-looking statements. Forward-looking statements
include, among other things, statements regarding the Company being
able to access the DIP financing, the CCAA Order not being
successfully appealed and obtaining a successful result in connection
with the arbitration. Forward-looking statements are necessarily
based upon a number of estimates and assumptions that, while
considered reasonable by the Company, are inherently subject to
significant business, economic, financial, competitive, political and
social uncertainties and contingencies. Many factors could cause the
Company’s actual results to differ materially from those expressed or
implied in any forward-looking statements made by, or on behalf of,
the Company, including the failure by the Company to draw down under
the DIP financing facility. Investors are cautioned that
forward-looking statements are not guarantees of future performance
and, accordingly, investors are cautioned not to put undue reliance
on forward-looking statements due to the inherent uncertainty
therein. For more information on the risks, uncertainties and
assumptions that could cause the Company’s actual results to differ
from current expectations, please refer to the Company’s public
filings available under the Company’s profile on SEDAR at
www.sedar.com (including, in particular, the “Risk Factors” section
of the Company’s annual information form dated March 31, 2011 and the
Company’s management’s discussion and analysis of financial position
and results of operations for the nine month period ended September
30, 2011, incorporated herein by reference) and the documents
relating to the CCAA proceedings available on the Monitor’s website.
Forward-looking statements are made as of the date of this press
release, and the Company disclaims any intent or obligation to update
publicly such forward-looking statements, whether as a result of new
information, future events or results or otherwise, except as
required by law.
Contacts:
Investor Relations Contact:
Crystallex International Corporation
Richard Marshall, VP
(800) 738-1577
info@crystallex.com
www.crystallex.com
SOURCE: Crystallex International Corporation
mailto:info@crystallex.com
http://www.crystallex.com
Copyright 2012 Marketwire, Inc., All rights reserved.
Financial Glossary
Words used in this article:
May 10, 2012
TORONTO, April 23, 2012 /PRNewswire via COMTEX/ –
TSX: CLQ; U.S. OTCQX: CLQMF
Canada Lithium Corp.
/quotes/zigman/9361 CA:CLQ
+2.22%
(otcqx:CLQMF) announced today it has finalized and signed an aggregate of C$92
million of financing facilities for the construction and development of
Canada Lithium’s Québec Lithium open pit mine and process plant near
Val d’Or, Québec. As announced in the press release of February 13,
2012, the financing facilities comprise a C$75-million project debt
facility and a US$17-million lease facility for the mobile mining
equipment. The Project debt facility will be supported by a financial
guarantee from Investissement Québec and will be provided by The Bank
of Nova Scotia and Caterpillar Financial Services (“Cat Financial”).
Drawdown of the financing facilities is subject to standard project and
lease financing conditions, including permitting requirements and
completion of the final project funding requirements.
As part-consideration to Investissement Québec, the Company has obtained
TSX approval to grant five-year warrants, to be issued at drawdown. In
addition, Cat Financial has been issued 100,000 Warrants at an exercise
price of $0.61.
Project Update – Construction on Schedule and on Budget
Construction of the Québec Lithium Project began in August 2011.
Completion of the integrated mine and lithium carbonate processing
facility has now reached a milestone stage with work commencing inside
the concentrator building for the installation of the ball mills and
flotation circuits. Major equipment long-lead items such as crushers,
ball mills, electrical sub-station, kiln and hydrometallurgical
components have commenced arriving on-site.. Commissioning of the
US$207-million project is scheduled to commence in late 2012, and the
Company is continuing discussions in respect of lithium carbonate
off-take agreements with a number of potential customers. Sales of
battery-grade lithium carbonate are anticipated to begin late in the
first quarter of 2013. At full production, the Québec Lithium Project
would produce in excess of 20,000 tonnes of battery-grade lithium
carbonate per year.
Photographs of the site construction work can be viewed at
www.canadalithium.com . Canada Lithium is being advised on the financing of the Québec Lithium
Project by Endeavour Financial.
About Canada Lithium Corp.
The Company holds a 100% interest in the Québec Lithium Project near Val
d’Or, the geographical heart of the Québec mining industry. The Company
is in the midst of building an open-pit mine and processing plant
on-site with capacity to produce approximately 20,000 tonnes of
battery-grade lithium carbonate. Metallurgical tests have produced
battery-grade lithium carbonate samples. The Company trades under the
symbol CLQ on the TSX and on the U.S. OTCQX under the symbol CLQMF.
About Endeavour Financial
Endeavour Financial is a private independent merchant banking company
focused on providing expert and unbiased financial advisory services to
the global natural resources sector. Endeavour Financial has a history
of achieving success for clients based on resource industry focus,
innovative transaction skills and the diverse professional backgrounds
of its award-winning team. Offering advice in project, corporate and
debt capital markets; equity-linked financings; mergers and
acquisitions; and strategic business development over more than two
decades, Endeavour Financial has established itself as a leading
financial advisor in the natural resources sector. Specific to the
mining sector, in the last ten years the firm has closed in excess of
US$ 4 billion of development financings for single-asset emerging
producers.
Cautionary Statement Regarding Forward-Looking Information
This press release contains “forward-looking information” within the
meaning of applicable Canadian securities legislation. Generally,
forward-looking information can be identified by the use of
forward-looking terminology such as “plans”, “expects” or “does not
expect”, “is expected”, “budget”, “scheduled”, “estimates”,
“forecasts”, “intends”, “anticipates” or “does not anticipate”, or
“believes”, or variations of such words and phrases or statements that
certain actions, events or results “may”, “could”, “would”, “might” or
“will be taken”, “occur” or “be achieved”.
Forward-looking information is based on reasonable assumptions that have
been made by the Corporation as at the date of such information and is
subject to known and unknown risks, uncertainties and other factors
that may cause the actual results, level of activity, performance or
achievements of the Corporation to be materially different from those
expressed or implied by such forward-looking information.
Although the Company has attempted to identify important factors that
could cause actual results to differ materially from those contained in
forward-looking information, there may be other factors that cause
results not to be as anticipated, estimated or intended. There can be
no assurance that such information will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such information. Accordingly, readers should not place
undue reliance on forward-looking information. The Corporation does not
undertake to update any forward-looking information referenced herein,
except in accordance with applicable securities laws.
SOURCE CANADA LITHIUM CORP.
Copyright (C) 2012 PR Newswire. All rights reserved
/quotes/zigman/9361
Add to portfolio
CA:CLQ
Canada Lithium Corp.
CA
: Canada: Toronto
$
0.46
+0.01
+2.22%
Volume: 846,903
May 9, 2012 1:39p
P/E RatioN/A
Dividend YieldN/A
Market Cap$113.73 million
Rev. per EmployeeN/A
Financial Glossary
Words used in this article:
May 9, 2012
By Leonard Baron
NEW YORK (Zillow.com) — These days, many people hear in the news that it’s a good time to buy rental property, so they’ve decided that they would like to get started in the property rental business, (aka. being a landlord).
But, in order to get into the rental property investment business, how do you obtain mortgage financing to purchase your first rental property? It’s true that it has become a lot harder to get financing these days; but for people with decent credit and sufficient income there is still plenty of money available to borrow. For terminology purposes, when you borrow for a rental property, it is called non-owner occupant (NOO) financing. Let’s run through some financing issues, items and suggestions that may help you.
May 9, 2012
BOULDER, Colo., Apr 24, 2012 (BUSINESS WIRE) –
–New investor Remeditex Ventures leads the round joining all existing investors
MiRagen Therapeutics, Inc., a biopharmaceutical company developing
innovative microRNA (miRNA)-based therapeutics primarily for the
treatment of patients who suffer from cardiovascular and muscle disease,
announced today the completion of a $20 million Series B financing. The
financing is being led by Remeditex Ventures, LLC, with participation
from miRagen’s existing investor syndicate, which includes Atlas
Venture, Boulder Ventures Ltd., Amgen Ventures, and Broadview Ventures.
The funding enables miRagen to advance the development of its compelling
microRNA-based therapeutics pipeline.
“The Series B financing provides further validation of miRagen and the
promise of microRNA-based therapeutics,” said William S. Marshall,
Ph.D., President and Chief Executive Officer. “This funding strengthens
our ability to advance novel microRNA-based therapeutics that may
address areas of high unmet medical need and improve the lives of
patients. We are thankful to have a committed syndicate of investors and
excited to welcome Remeditex to the team.”
“In a short period of time, miRagen has delivered significant advances
that help to translate new biology into next generation therapeutic
candidates,” said Bruce Booth, D.Phil., miRagen’s Chairman of the Board
and Partner, Atlas Venture. “The team has generated these compelling
results in a capital efficient manner, and we look forward to moving the
company to the logical next level with the Series B investment.”
“We are excited to be a part of the high quality team at miRagen and to
help advance the company’s promising therapeutics,” said John Creecy,
Chief Executive Officer and Director at Remeditex Ventures. “We believe
this science can be life changing for the many that have so few options
today, and that miRagen is well positioned for success in making that
happen.”
About microRNAs: MicroRNAs have emerged as an important class of
small RNAs encoded in the genome. They act to control the expression of
sets of genes and entire pathways and are thus thought of as master
regulators of gene expression. Recent studies have demonstrated that
microRNAs are associated with many disease processes. Because they are
single molecular entities that dictate the expression of fundamental
regulatory pathways, microRNAs represent potential drug targets for
controlling many biologic and disease processes.
About miRagen Therapeutics: MiRagen Therapeutics, Inc., is a
biopharmaceutical company founded to harness the power of microRNA
(miRNA) biology and develop innovative microRNA-based therapeutics for
cardiovascular and muscle disease. In October 2011, miRagen and Les
Laboratoires Servier, a leading European pharmaceutical company, entered
into a strategic alliance for the research and development of
microRNA-based therapeutics for the treatment of patients afflicted with
cardiovascular disease. Combining in-house expertise in microRNA biology
and chemistry with strong external partnerships and academic
collaborations, miRagen is striving to make a difference in health care
across the globe. For more information, please visit
www.miragenrx.com .
SOURCE: miRagen Therapeutics
For miRagen
Kecia Carroll, Communications
720-933-0848
Kecia@kcroberg.com
Copyright Business Wire 2012
Financial Glossary
Words used in this article:
May 7, 2012
Embraer has signed a memorandum of understanding with Chinas ICBC Financial Leasing under which ICBC will provide up to USD$2.5 billion in financing for planes over five years in one of Embraers most promising markets.
Embraer expects demand for 430 commercial jets of up to 120-seat capacity and 635 executive jets in the next 10 years in the fast-growing Asian giant.
The rapid development of the Chinese economy has resulted in high growth rates for regional and executive aviation, making it one of the greatest potential markets in the world, Paulo Cesar de Souza e Silva, Embraers head of commercial aviation, said in a press release.
ICBC Financial Leasing is a wholly-owned subsidiary of the Industrial and Commercial Bank of China with a business spanning shipping and large equipment as well as aviation. It has more than 70 jets in its portfolio and plans to expand that to 250 by 2014, according to the release.
Embraer entered the Chinese market in 2000 and has since received 153 firm orders for commercial and executive jets, with more than 110 delivered. The company now accounts for three-quarters of Chinas market for commercial jets of up to 120 seats.
May 7, 2012
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| « Apr | ||||||
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 | |||